146 related articles for article (PubMed ID: 8233262)
1. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas.
Rein MS; Barbieri RL; Welch W; Gleason RE; Caulfield JP; Friedman AJ
Obstet Gynecol; 1993 Dec; 82(6):901-5. PubMed ID: 8233262
[TBL] [Abstract][Full Text] [Related]
2. Leuprolide acetate treatment and myoma arterial size.
Rutgers JL; Spong CY; Sinow R; Heiner J
Obstet Gynecol; 1995 Sep; 86(3):386-8. PubMed ID: 7651647
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
4. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
5. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
6. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group.
Friedman AJ; Hoffman DI; Comite F; Browneller RW; Miller JD
Obstet Gynecol; 1991 May; 77(5):720-5. PubMed ID: 1901638
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata.
Schlaff WD; Zerhouni EA; Huth JA; Chen J; Damewood MD; Rock JA
Obstet Gynecol; 1989 Dec; 74(6):856-62. PubMed ID: 2511532
[TBL] [Abstract][Full Text] [Related]
8. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
10. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy.
Cohen D; Mazur MT; Jozefczyk MA; Badawy SZ
J Reprod Med; 1994 May; 39(5):377-80. PubMed ID: 7520497
[TBL] [Abstract][Full Text] [Related]
11. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
12. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist.
Rein MS; Friedman AJ; Pandian MR; Heffner LJ
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):388-94. PubMed ID: 2116610
[TBL] [Abstract][Full Text] [Related]
13. [Size reduction of uterine myomas with monthly administered leuprolide acetate].
Cheviakoff S; Bocaz JA; Martínez L; Romero C
Rev Chil Obstet Ginecol; 1994; 59(6):416-20; discussion 420-1. PubMed ID: 7569160
[TBL] [Abstract][Full Text] [Related]
14. Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Kalir T; Goldstein M; Dottino P; Brodman M; Gordon R; Deligdisch L; Wu H; Gil J
Arch Pathol Lab Med; 1998 May; 122(5):442-6. PubMed ID: 9593346
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of GnRH agonists in preoperative treatment of complicated uterine myomata].
Campusano C; Zapata R; Bianchi M; Badia JI; Arteaga E
Rev Chil Obstet Ginecol; 1993; 58(2):150-4. PubMed ID: 8209044
[TBL] [Abstract][Full Text] [Related]
16. Submucous myomas treated with gonadotropin releasing hormone agonist and resulting in vaginal hemorrhage. A case report.
Thorp JM; Katz VL
J Reprod Med; 1991 Aug; 36(8):625-6. PubMed ID: 1941808
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin releasing hormone (GnRH) agonist therapy for reduction of leiomyoma volume.
Murphy NJ; Wallace DL
Gynecol Oncol; 1993 May; 49(2):266-7. PubMed ID: 8504999
[TBL] [Abstract][Full Text] [Related]
18. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
Stolz W; Pfützenreuter N
Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones.
Malik M; Britten J; Cox J; Patel A; Catherino WH
Fertil Steril; 2016 Jan; 105(1):214-24. PubMed ID: 26409322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
